Hematology & Blood Cancer
Hematology & Blood Cancer
Leah LawrenceHematology & Blood Cancer | October 12, 2022
Care teams at Thomas Jefferson University Hospital decreased time to chemotherapy administration by using new strategies.
Read More
Leah LawrenceHematology & Blood Cancer | September 20, 2022
ICANS, a complication of CAR T cell therapy, was associated with an injury that is detectable with a blood test.
Emily MenendezHematology & Blood Cancer | September 1, 2022
The tablet form of blood cancer drug acalabrutinib has been FDA approved, making administration easier for certain patients.
Teresa Hagan Thomas, PhD, RNTreatment | July 12, 2022
One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | June 27, 2022
Patients who receive a transplant at a young age may experience GVHD symptoms decades later, like oral chronic GVHD.
Patrick DalyHematology & Blood Cancer | March 24, 2022
Anti-thymocyte globulin (ATG) is used in conditioning prior to allogeneic hematopoietic stem cell transplantation for acute ...
Ariel JonesConferences | December 18, 2021
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Ariel JonesConferences | December 17, 2021
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Ariel JonesConferences | December 17, 2021
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Ariel JonesConferences | December 16, 2021
This lack of benefit was seen in the entire study population.
Ariel JonesConferences | December 16, 2021
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
Ariel JonesConferences | December 16, 2021
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
Ariel JonesConferences | December 16, 2021
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
Ariel JonesConferences | December 14, 2021
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Ariel JonesConferences | December 14, 2021
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.
Ariel JonesConferences | December 14, 2021
“The results of ZUMA-7 herald a paradigm shift in how we treat large B-cell lymphoma."
Patrick DalyLeukemia | November 29, 2021
Researchers, led by Katharine McLaughlin, examined the relationship between changes in vital signs and admission to an ...
Patrick DalyLeukemia | November 29, 2021
Researchers performed a meta-analysis to evaluate two hypomethylating agents (HMAs), decitabine and azacitidine, in the ...
Patrick DalyLeukemia | November 29, 2021
Findings from a randomized trial, published in The Lancet Oncology, showed that combining enasidenib with azacitidine was ...
Patrick DalyLeukemia | November 29, 2021
Researchers developed a method to measure standardized intracellular reactive oxygen species (siROS) levels in the CD34+ bone ...
Advertisement
Advertisement